Biomarker concordance between primary colorectal cancer and its metastases von Bhullar, D.S., Barriuso, J., Mullamitha, S., Saunders, M.P., O'Dwyer, S.T., Aziz, O.

Volltext

A phase II study of retifanlimab (INCMGA00012) in patients with squamous carcinoma of the anal canal who have progressed following platinum-based chemotherapy (POD1UM-202) von Rao, S., Anandappa, G., Capdevila, J., Dahan, L., Evesque, L., Kim, S., Saunders, M.P., Gilbert, D.C., Jensen, L.H., Samalin, E., Spindler, K.-L., Tamberi, S., Demols, A., Guren, M.G., Arnold, D., Fakih, M., Kayyal, T., Cornfeld, M., Tian, C., Catlett, M., Smith, M., Spano, J.-P.

Volltext

Clinico-pathological predictors of clinical complete response in rectal cancer von Mbanu, P., Osorio, E. Vasquez, Mistry, H., Malcomson, L., Yousif, S., Aznar, M., Kochhar, R., Van Herk, M., Renehan, A.G., Saunders, M.P.

Volltext

Trifluridine/tipiracil in combination with oxaliplatin and either bevacizumab or nivolumab in metastatic colorectal cancer: a dose-expansion, phase I study von Bordonaro, R., Calvo, A., Auriemma, A., Hollebecque, A., Rubovszky, G., Saunders, M.P., Pápai, Z., Prager, G., Stein, A., André, T., Argilés, G., Cubillo, A., Dahan, L., Edeline, J., Leger, C., Cattan, V., Fougeray, R., Amellal, N., Tabernero, J.

Volltext

SP-0104: DREAMtherapy trial of novel rectal chemoradiotherapy von Marti, F, Backen, A, Renehan, A.G, Manoharan, P, Misra, V, Jackson, A, Jayson, G, Dive, C, Saunders, M.P

Volltext

Trifluridine/tipiracil plus bevacizumab in patients with untreated metastatic colorectal cancer ineligible for intensive therapy: the randomized TASCO1 study von Van Cutsem, E., Danielewicz, I., Saunders, M.P., Pfeiffer, P., Argilés, G., Borg, C., Glynne-Jones, R., Punt, C.J.A., Van de Wouw, A.J., Fedyanin, M., Stroyakovskiy, D., Kroening, H., Garcia-Alfonso, P., Wasan, H., Falcone, A., Kanehisa, A., Egorov, A., Aubel, P., Amellal, N., Moiseenko, V.

Volltext

519P The efficacy of oxaliplatin desensitisation protocol in patients with GI malignancies von Christodoulis, E., Vlachostergios, P.J., Connell, J., Williams, J., Hasan, J., Mansoor, W., Mullamitha, S., Hubner, R., Braun, M., Saunders, M.P., Barriuso, J., Waddell, T.S., Alam, N., Kamposioras, K.V.

Volltext

Oxaliplatin and 5-FU/folinic acid (modified FOLFOX6) with or without aflibercept in first-line treatment of patients with metastatic colorectal cancer: the AFFIRM study von Folprecht, G., Pericay, C., Saunders, M.P., Thomas, A., Lopez Lopez, R., Roh, J.K., Chistyakov, V., Höhler, T., Kim, J.-S., Hofheinz, R.-D., Ackland, S.P., Swinson, D., Kopp, M., Udovitsa, D., Hall, M., Iveson, T., Vogel, A., Zalcberg, J.R.

Volltext

135P Exploring discrepancies in perception: A study of patients' and health professionals' understanding of cancer care von Christodoulis, E., Ntellas, P., Dadouli, K., Simpson, L., Lim, K.H.J., Shanthappa, A., Connell, J., Williams, J., Anderson, D., Hasan, J., Mullamitha, S., Braun, M., Marti, K., Adamou, M., Saunders, M.P., Barriuso, J., Kamposioras, K.V.

Volltext

426P Assessing nivolumab in class II expressing microsatellite stable (pMMR) colorectal cancer (CRC): Results of the ANICCA-Class II trial von Middleton, G., Liu, W., Savage, J., Bridgewater, J.A., Ross, P., Saunders, M.P., Plummer, R., Clive, S., Coyle, V., Thomas, A., P. Taniere, Billingham, L.

Volltext

SOLSTICE, a phase III, randomized, open label study of trifluridine/tipiracil+bevacizumab (bev) versus capecitabine+bev for the 1L treatment of patients with unresectable metastati... von Andre, T., Saunders, M.P., Kanehisa, A., Gandossi, E., Fougeray, R., Causse-Amellal, N., Falcone, A.

Volltext

665TiP - SOLSTICE, a phase III, randomized, open label study of trifluridine/tipiracil+bevacizumab (bev) versus capecitabine+bev for the 1L treatment of patients with unresectable... von Andre, T., Saunders, M.P., Kanehisa, A., Gandossi, E., Fougeray, R., Causse-Amellal, N., Falcone, A.

Volltext

568P Single cell AI-based detection of DNA mismatch repair deficiency in 1,988 colorectal cancers reveals prognostic and predictive value in the SCOT trial von Jabbar, F., Nowak, M., Rodewald, A-K., Gneo, L., Tomasevic, T., Harkin, A., Iveson, T.J., Saunders, M.P., Kerr, R., Oien, K.A., Maka, N., Hay, J., Edwards, J., Tomlinson, I., Sansom, O.J., Kelly, C., Easton, A., Domingo, E., Koelzer, V.H., Church, D.N.

Volltext

573P Multiparameter immunoprofiling reveals independent prognostic value of intraepithelial CD8 and intrastromal FoxP3 infiltrate in stage II/III colorectal cancer: Analysis of 3,4... von Church, D.N., Frei, A., McGuigan, A., Sinha, R., Harkin, A., Iveson, T.J., Saunders, M.P., Hay, J., Edwards, J., Sansom, O.J., Kelly, C., Kerr, R., Kerr, D.J., Domingo, E., Koelzer, V.H.

Volltext

1851P Psychological well-being of patients with colorectal cancer during the third wave of the COVID-19 pandemic: Results from cohort II of the PICO-SM study von Kamposioras, K.V., Dadouli, K., Ntellas, P., Lim, K.H.J., Adamou, M., Anderson, D., Simpson, L., Shanthappa, A., Braun, M., Barriuso, J., Connell, J., Williams, J., Lehwald, D., Hasan, J., Mullamitha, S., Marti, K., Saunders, M.P.

Volltext

LBA2 POD1UM-303/InterAACT 2: Phase III study of retifanlimab with carboplatin-paclitaxel (c-p) in patients (Pts) with inoperable locally recurrent or metastatic squamous cell carci... von Rao, S., Samalin-Scalzi, E., Evesque, L., Ben Abdelghani, M., Morano, F., Roy, A.C., Dahan, L., Tamberi, S., Dhadda, A.S., Saunders, M.P., Casanova, N., Guimbaud, R., Lievre, A., Maurel, J., Fakih, M., Zhang, P., Harrison, J., Jones, M., Spano, J-P., Rochefort, P.

Volltext

37P Phase II results of the porcupine (PORCN) inhibitor zamaporvint (RXC004) in genetically selected microsatellite stable colorectal cancer patients von Cook, N., Bridgewater, J.A., Saunders, M.P., Kopetz, S., Garcia-Carbonero, R., Beom, S-H., O'Neil, B.H., Wilson, R.H., Graham, J., Maurel, J., Kim, T.W., Chau, I., Saleha, S., Goodwin, L., Wilson, D., Robertson, J., Timmis, H., Asken, E., Woodcock, S.A., Morris, V.

Volltext

336P Prognostic and predictive value of Immunoscore in stage III colorectal cancer in the combined SCOT and IDEA-HORG studies von Church, D., Hay, J., Sansom, O.J., N. Maka, Oien, K.A., Iveson, T.J., Saunders, M.P., Edwards, J., Harkin, A., Boukovinas, I., Moustou, E., Messaritakis, I., Chondrozoumaki, M., Georgoulias, V., Boquet, I., Pages, F., Catteau, A., Galon, J., Kelly, C., Souglakos, I.

Volltext

Is it Time to Look for Better Prognostic Markers and Reconsider Adjuvant Chemotherapy for Locally Advanced Anal Cancers? von King, J., Swinton, M., Grant, G., Buckley, L., Lavin, V., Alam, N., Saunders, M.P.

Volltext

A phase Ib/ II trial to assess the safety and efficacy of CXD101 in combination with the PD-1 inhibitor nivolumab in patients with metastatic, previously-treated, microsatellite-st... von Saunders, M.P., Graham, J., Cunningham, D., Plummer, R., Cook, S., Church, D., Kerr, R., Thangue, N La, Kerr, D.J.

Volltext